Antibody Therapeutics(IF=4.5, Oxford University Press)
🎇🎇Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy
academic.oup.com/abt/article/...
#Bispecific #T_cell_engager
🎇🎇Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy
academic.oup.com/abt/article/...
#Bispecific #T_cell_engager
February 3, 2026 at 8:32 PM
Antibody Therapeutics(IF=4.5, Oxford University Press)
🎇🎇Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy
academic.oup.com/abt/article/...
#Bispecific #T_cell_engager
🎇🎇Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy
academic.oup.com/abt/article/...
#Bispecific #T_cell_engager
Mabwell Announces IND Clearance for Innovative Bispecific Antibody Targeting Hematologic Malignancies#China#Shanghai#Mabwell#T_Cell_Engager #6MW5311
Mabwell Announces IND Clearance for Innovative Bispecific Antibody Targeting Hematologic Malignancies
Mabwell has received IND clearance from China’s NMPA for its groundbreaking bispecific antibody 6MW5311, aimed at treating hematologic cancers.
third-news.com
June 24, 2026 at 12:10 AM
Mabwell Announces IND Clearance for Innovative Bispecific Antibody Targeting Hematologic Malignancies#China#Shanghai#Mabwell#T_Cell_Engager #6MW5311
Deck Bio Unveils Innovative Multi-pMHC T Cell Engager Platform at Two Major Conferences in 2026#United_States#San_Diego#Deck_Bio#DBXO-1#T_Cell_Engager
Deck Bio Unveils Innovative Multi-pMHC T Cell Engager Platform at Two Major Conferences in 2026
Deck Bio is set to showcase its cutting-edge multi-pMHC targeted T cell engager platform at the 8th T-Cell Engager Therapeutics Summit and BIO 2026.
third-news.com
June 18, 2026 at 5:07 PM
Deck Bio Unveils Innovative Multi-pMHC T Cell Engager Platform at Two Major Conferences in 2026#United_States#San_Diego#Deck_Bio#DBXO-1#T_Cell_Engager
Innovative Developments in Multi-pMHC Targeted T Cell Engagers Revealed by Deck Bio#United_States#San_Diego#Deck_Bio#DBXO-1#T_Cell_Engager
Innovative Developments in Multi-pMHC Targeted T Cell Engagers Revealed by Deck Bio
Deck Bio unveils pioneering preclinical findings on DBXO-1, a multi-pMHC targeted T cell engager, marking a significant advancement in cancer therapy.
third-news.com
April 20, 2026 at 12:13 PM
Innovative Developments in Multi-pMHC Targeted T Cell Engagers Revealed by Deck Bio#United_States#San_Diego#Deck_Bio#DBXO-1#T_Cell_Engager
Innovent Biologics Unveils Promising Data on IBI3055 for Autoimmune Treatment at Summit 2026#China#Suzhou#Innovent_Biologics#IBI3055#T_Cell_Engager
Innovent Biologics Unveils Promising Data on IBI3055 for Autoimmune Treatment at Summit 2026
Innovent Biologics presents preclinical results of IBI3055, a tri-specific T cell engager aimed at treating autoimmune diseases, at the Immune Resetting Summit 2026.
third-news.com
April 10, 2026 at 12:10 AM
Innovent Biologics Unveils Promising Data on IBI3055 for Autoimmune Treatment at Summit 2026#China#Suzhou#Innovent_Biologics#IBI3055#T_Cell_Engager